A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis

Vaccine

Volumn 27, Issue 7, 2009, Pages 1080-1086

  Carson, Connor ^a   Antoniou, Maria ^b   Ruiz Argüello, Maria Begoña ^c   Alcami, Antonio ^c   Christodoulou, Vasiliki ^b   Messaritakis, Ippokratis ^b   Blackwell, Jenefer M ^d   Courtenay, Orin ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Leishmania infantum; Prime boost DNA MVA vaccination; Tryparedoxin peroxidase

Indexed keywords

DNA TRYPAREDOXIN PEROXIDASE VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 10; LEISHMANIA HOMOLOGUE OF THE MAMMALIAN RECEPTOR FOR ACTIVATED C KINASE; LEISHMANIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA TRYPAREDOXIN PEROXIDASE VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; PEROXIDASE; PLASMID DNA; PRIMER DNA; RECOMBINANT DNA; RECOMBINANT VACCINE; TRYPAREDOXIN PEROXIDASE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DOG; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; LEISHMANIA INFANTUM; LOW DRUG DOSE; MALE; NONHUMAN; OUTBRED STRAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN MANIFESTATION; TH2 CELL; VACCINATION; VIRUS RECOMBINANT; VISCERAL LEISHMANIASIS; ZOONOSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DOGS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEISHMANIA INFANTUM; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; PEROXIDASES; PROTOZOAN PROTEINS; VACCINES, DNA; VACCINIA VIRUS;

EID: 58949091409     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.094     Document Type: Article

References (59)

1. Mauricio I.L., Stothard J.R., and Miles M.A. The strange case of Leishmania chagasi. Parasitol Today 16 5 (2000) 188-189
2. WHO/TDR. http://www.who.int/tdr/diseases/leish/direction.htm, 2002.
3. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55 2 (1996) 125-130
4. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., and Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 186 9 (2002) 1314-1320
5. ® vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol 141 1-2 (2006) 1-8
6. Borja-Cabrera G.P., Pontes N.N.C., da Silva V.O., de Souza E.P., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20 27-28 (2002) 3277-3284
7. ® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 12 (2007) 2180-2186
8. Mendez S., Gurunathan S., Kamhawi S., Belkaid Y., Moga M.A., Skeiky Y.A.W., et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166 8 (2001) 5122-5128
9. Dumonteil E. DNA vaccines against protozoan parasites: Advances and challenges. J Biomed Biotechnol 2007; Article 90520.
10. Levick M.P., Blackwell J.M., Connor V., Coulson R.M.R., Miles A., Smith H.E., et al. An expressed sequence tag analysis of a full-length, spliced-leader cDNA library from Leishmania major promastigotes. Mol Biochem Parasit 76 1-2 (1996) 345-348
11. Levick M.P., Tetaud E., Fairlamb A.H., and Blackwell J.M. Identification and characterisation of a functional peroxidoxin from Leishmania major. Mol Biochem Parasit 96 1-2 (1998) 125-137
12. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 7 (1998) 3279-3289
13. Almeida R., Norrish A., Levick M., Vetrie D., Freeman T., Vilo J., et al. From genomes to vaccines: Leishmania as a model. Philos T Roy Soc B 357 1417 (2002) 5-11
14. Stober C.B., Lange U.G., Roberts M.T.M., Alcami A., and Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 175 4 (2005) 2517-2524
15. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Skeiky Y.A.W., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69 6 (2001) 4103-4108
16. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24 21 (2006) 4554-4561
17. Stober C.B., Lange U.G., Roberts M.T.M., Alcami A., and Blackwell J.M. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice. Infect Immun 75 2 (2007) 852-860
18. Jacob J., and Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature 399 6736 (1999) 593-597
19. Mougneau E., Altare F., Wakil A.E., Zheng S.C., Coppola T., Wang Z.E., et al. Expression cloning of a protective Leishmania antigen. Science 268 5210 (1995) 563-566
20. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
21. Ramos I., Alonso A., Marcen J.M., Peris A., Castillo J.A., Colmenares M., et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26 3 (2008) 333-344
22. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 4 (1998) 397-402
23. Mayr A., and Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41 (1978) 225-234
24. Meyer R.G., Britten C.M., Siepmann U., Petzold B., Sagban T.A., Lehr H.A., et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immun 54 5 (2005) 453-467
25. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20 15 (2002) 1949-1955
26. Moorthy V.S., Pinder M., Reece W.H.H., Watkins K., Atabani S., Hannan C., et al. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in african adults. J Infect Dis 188 8 (2003) 1239-1244
27. McShane H., Brookes R., Gilbert S.C., and Hill A.V.S. Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69 2 (2001) 681-686
28. Palmowski M.J., Choi E.M.L., Hermans I.F., Gilbert S.C., Chen J.L., Gileadi U., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 9 (2002) 4391-4398
29. Gradoni L, Gramiccia M. Leishmaniosis. In: OIE manual of standards for diagnostic tests and vaccines for terrestrial animals. 4th ed. Paris, France, Office International des Epizooties, 2004: 803-12.
30. Quinnell R.J., Courtenay O., Garcez L., and Dye C. The epidemiology of canine leishmaniasis: Transmission rates estimated from a cohort study in Amazonian Brazil. Parasitology 115 2 (1997) 143-156
31. Parvizi P., Mauricio I., Aransay A.M., Miles M.A., and Ready P.D. First detection of Leishmania major in peridomestic Phlebotomus papatasi from Isfahan province, Iran: Comparison of nested PCR of nuclear ITS ribosomal DNA and semi-nested PCR of minicircle kinetoplast DNA. Acta Trop 93 1 (2005) 75-83
32. UK Home Office. Code of practice for the housing and care of animals used in scientific procedures (1989). http://scienceandresearch.homeoffice.gov.uk/animal-research.
33. Alexander B. Sampling methods for phlebotomine sandflies. Med Vet Entomol 14 2 (2000) 109-122
34. European Medicines Agency: Evaluation of the safety of veterinary medicinal products for the target animals. 7AE2a 1994; vol. 7.
35. Shifrine M., Taylor N.J., Rosenblatt L.S., and Wilson F.D. Comparison of whole-blood and purified canine lymphocytes in a lymphocyte-stimulation microassay. Am J Vet Res 39 4 (1978) 687-690
36. Tijssen P. Practice and theory of enzyme immunoassays. 1st ed. (1985), Amsterdam Elsevier Science Publishers B.V.
37. Pinelli E., Killick-kendrick R., Wagenaar J., Bernadina W., Delreal G., and Ruitenberg J. Cellular and humoral immune-responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62 1 (1994) 229-235
38. Mackett M., Smith G.L., and Moss B. The construction and characterization of vaccinia virus recombinants expressing foreign genes. In: Glover D.M. (Ed). DNA Cloning: A Practical Approach (1985), IRL Oxford 191-211
39. European Medicines Agency: Specific requirements for the production and control of live and inactivated viral and bacterial vaccines for cats and dogs 7BIm13a 1995; vol. 7.
40. European Commission: Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes (1986). http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm.
41. Kaye P.M., Curry A.J., and Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146 8 (1991) 2763-2770
42. Ferreira J.H.L., Gentil L.G., Dias S.S., Fedeli C.E.C., Katz S., and Barbieri C.L. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis. Vaccine 26 5 (2008) 677-685
43. Wilson M.E., Jeronimo S.M.B., and Pearson R.D. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathogenesis 38 4 (2005) 147-160
44. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
45. Pinelli E., Gonzalo R.M., Boog C.J.P., Rutten V., Gebhard D., Delreal G., et al. Leishmania infantum-specific T-Cell lines derived from asymptomatic dogs that lyse infected macrophages in a Major Histocompatibility Complex-restricted manner. Eur J Immunol 25 6 (1995) 1594-1600
46. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi F., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 28 (2005) 3716-3725
47. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 21 (2007) 4223-4234
48. Fujiwara R.T., Vale A.M., Franca Da Silva J.C., Da Costa R.T., Quetz J.D.S., Martins Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36 5-6 (2005) 827-838
49. Day M.J. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Veterinary Parasitol 147 1-2 (2007) 2-8
50. Reed S.G., and Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 5 4 (1993) 524-531
51. Reiner S.L., and Locksley R.M. Lessons from Leishmania-a model for investigations of Cd4+ subset differentiation. Infect Agent Dis 1 1 (1992) 33-42
52. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17 3 (1996) 138-146
53. Barbieri C.L. Immunology of canine leishmaniasis. Parasite Immunol 28 7 (2006) 329-337
54. Pinheiro P.H.D., Dias S.D., Eulalio K.D., Mendonca I.L., Katz S., and Barbieri C.C. Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses. Infect Immun 73 6 (2005) 3787-3789
55. Chamizo C., Moreno J., and Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 103 1-2 (2005) 67-75
56. Santos-Gomes G.M., Rosa R., Leandro C., Cortes S., Romao P., and Silveira H. Cytokine expression during the outcome of canine experimental infection by Leishmania infantum. Vet Immunol Immunopathol 88 1-2 (2002) 21-30
57. Quinnell R.J., Courtenay O., Shaw M.A., Day M.J., Garcez L.M., Dye C., et al. Tissue cytokine responses in canine visceral leishmaniasis. J Infect Dis 183 9 (2001) 1421-1424
58. Goto Y., Bogatzki L.Y., Bertholet S., Coler R.N., and Reed S.G. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25 42 (2007) 7450-7458
59. Moreno J., Nieto J., Masina S., Canavate C., Cruz I., Chicharro C., et al. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25 29 (2007) 5290-5300